Palomar Medical Technologies Inc. won a pair of patent opposition cases in Europe involving its laser hair removal technology.
The European Patent Office upheld the Burlington-based cosmetic laser device maker’s patents as “novel and inventive” over its competitors.
The company said it’s licensed the technologies to 10 other companies and has received more than $80 million in royalties for their use.
CFO Paul Weiner told MassDevice that the win in Europe helps on two fronts.
“There are two factors. It really validates the strength of these patents,” Weiner said. “The other factor is that with Syneron, they do not owe us royalties on the fact that they’re manufacturing in Israel. They only owe us royalties for countries that they are selling products into where we have patents.”
Based on the Israeli company’s first-quarter sales and earnings, he added, that means roughly 80 percent of Syneron’s sales in the United States, Japan, Europe and elsewhere could be subject to royalties owed to Palomar.
Weiner said that in addition to its 10 licensing agreements, Palomar inked a $5 million-a-year deal with Procter & Gamble that licenses its hair removal technology to the consumer products conglomerate for a home-based device.
Palomar has a similar agreement with Johnson & Johnson for a home-based anti-aging device, he said.